Marijuana Company of America, Inc. (MCOA) Offers All-Natural Hemp-Derived CBD Products to Consumers

  • Opioid epidemic driving search for safer, all-natural alternatives
  • Recent studies indicate that CBD may be an effective treatment for certain ailments
  • Relaxation on hemp cultivation could pave the way for distribution of CBD products

The continued scourge of opioid addiction across America is intensifying efforts to find safer alternatives to the use of narcotics. Drug overdose deaths are now the leading cause of death for Americans under the age of 55, knocking heart disease from the top position, according to The New York Times (http://cnw.fm/N25hG). As a result, the population mortality rate, on the decline since 1963, is rising again. Preliminary data indicates that it rose in 2017, marking possibly, the “third straight year of decline in American life expectancy rates,” Bloomberg reports (http://cnw.fm/7QJ0v). Still, powerful opioids like fentanyl continue to be employed in pain management regimens. Recent studies on the use of safer alternatives to manage one’s health, particularly cannabidiol (CBD), are gaining attention.

Coupled with relaxed restrictions on hemp cultivation, this has opened up a vista of opportunity for Marijuana Company of America (OTC: MCOA). Through wholly owned subsidiary hempSMART™, the company delivers all of the benefits of hemp-derived cannabidiol products, employing its unique affiliate marketing and distribution platform. MCOA is intent on building a portfolio of companies that operate in the legal cannabis and industrial hemp industries.

A number of recent studies, highlighted by a CBDWire release, indicate that CBD could be a safe alternative to perniciously addictive opioids (http://cnw.fm/CjEi0). Moreover, CBD is one component in Sativex, which has been approved for use in treating chronic pain in Canada and Europe. The World Health Organization (WHO), in late 2017, issued a statement, after studying CBD, that reads in part, “In humans, CBD exhibits no effects indicative of any abuse or dependence potential… To date, there is no evidence of recreational use of CBD or any public health related problems associated with the use of pure CBD.” These developments appear to be removing the stigma that CBD has acquired by being a derivative of the cannabis plant.

The growing interest in CBD has come at a time when efforts to ease restrictions on the cultivation of hemp in the U.S. are underway. For example, a number of states have introduced legislation and regulations allowing for the cultivation of hemp, from which CBD oil can be extracted. Earlier this year, the Hemp Farming Act, which proposes, among other things, to remove hemp from Schedule 1 of the CSA, was introduced in the U.S. Senate. As part of its hemp promotion initiative, the Senate also declared June 4-10 to be “Hemp History Week”. This hemp hurrah comes after an exile of 60 years. Commercial cultivation of hemp in the U.S. effectively ceased after 1958.

Together with joint venture partner Global Hemp Group (CSE: GHG) (OTC: GBHPF), Marijuana Company of America is already executing its plans to cultivate hemp on a commercial basis in North America, with current operations underway in New Brunswick, Canada, and Oregon.  After promising results from the 2017 season, the two companies intend to plant a minimum of 125 acres of hemp in New Brunswick this year, increasing that, over the following three years, to 1,000 acres.

For more information, visit the company’s website at www.MarijuanaCompanyofAmerica.com

More from CannabisNewsWire

About CBDWire

CBDWire (CBDW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CBDNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge.

For more information please visit https://www.cbdwire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

CBDWire (CBDW)
Denver, Colorado
cbdwire.com
303.498.7722 Office
Editor@CBDWire.com

Archives

Select A Month

CBDWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 303.498.7722